Bharat Biotech says supply chains not impacted by Russia-Ukraine conflict

Bharat Biotech said recently the Russia-Ukraine conflict had not impacted the company’s supply chains so far.

A few Indian pharma companies have a presence in Russia, exporting and selling medicines in the country. Sales to Russia between April and December last year reached $386 million, or 15 per cent of the total exports to the country.

Of late, Dr Reddy’s Laboratories said it was focussed on business continuity in and around Russia, while executives from Torrent Pharma and Zydus Lifesciences said they saw little or no sales impact due to the conflict.

Production of Bharat Biotech’s homegrown COVID-19 vaccine Covaxin “has been fully indigenised, all Active Pharmaceutical Ingredients (APIs) and critical raw materials are manufactured within India,” the company said in an emailed statement.

“This was always a strategic decision at Bharat Biotech to develop and commercialise technologies developed within India and to reduce dependence on external sources,” it added.

Bharat Biotech’s COVID-19 shot Covaxin has accounted for 16.5 per cent of the nearly 1.80 billion vaccine doses that have been administered to the Indian population so far.

Edits by EP News Bureau